H. Res. 1155 
In the House of Representatives, U. S., 
May 12, 2010. 
Whereas tuberculosis (hereafter in this preamble referred to 
as ‘‘TB’’) is the second leading fatal global infectious dis-
ease behind HIV/AIDS, claiming 1,800,000 million lives 
each year; 
Whereas the global TB pandemic and the spread of drug re-
sistant TB present a persistent public health threat to 
the United States; 
Whereas according to 2009 data of the World Health Organi-
zation, 5 percent of all new TB cases are drug resistant; 
Whereas TB is the leading killer of people with HIV/AIDS; 
Whereas TB is the third leading killer of adult women, and 
the stigma associated with TB disproportionately affects 
women, causing them to delay seeking care and inter-
fering with treatment adherence; 
Whereas the Institute of Medicine (IOM) found that the re-
surgence of TB between 1980 and 1992 was caused by 
cuts in TB control funding and the spread of HIV/AIDS; 
Whereas, although the numbers of TB cases in the United 
States continue to decline, progress towards TB elimi-
nation has slowed, and it is a disease that does not recog-
nize borders;
•HRES 1155 EH 
Whereas New York City had to spend over $1,000,000,000 
to control a multi-drug resistant TB outbreak between 
1989 and 1993; 
Whereas an extensively drug resistant form of TB, known as 
XDR-TB (hereafter referred to in this preamble as 
‘‘XDR-TB)’’), is very difficult and expensive to treat and 
has high and rapid fatality rates, especially among HIV/ 
AIDS patients; 
Whereas the United States has had more than 83 cases of 
XDR-TB over the last decade; 
Whereas the Centers for Disease Control and Prevention esti-
mated in 2009 that it costs $483,000 to treat a single 
case of XDR-TB; 
Whereas African Americans are 8 times more likely to have 
TB than Caucasians, and significant disparities exist 
among other United States minorities, including Native 
Americans, Asian Americans, and Hispanic Americans; 
Whereas, although drugs, diagnostics and vaccines for TB 
exist, these technologies are antiquated and are increas-
ingly inadequate for controlling the global epidemic; 
Whereas the most commonly used TB diagnostic in the 
world, sputum microscopy, is more than 100 years old 
and lacks sensitivity to detect TB in most HIV/AIDS pa-
tients and in children; 
Whereas current tests to detect drug resistance take at least 
1 month to complete and faster drug susceptibility tests 
must be developed to stop the spread of drug resistant 
TB; 
Whereas the TB vaccine, BCG, provides some protection to 
children, but has little or no efficacy in preventing pul-
monary TB in adults;
•HRES 1155 EH 
Whereas there is also a critical need for new TB drugs that 
can safely be taken concurrently with antiretroviral ther-
apy for HIV; 
Whereas enactment of the Tom Lantos and Henry J. Hyde 
United States Global Leadership Against HIV/AIDS, Tu-
berculosis, and Malaria Reauthorization Act of 2008 and 
the Comprehensive TB Elimination Act provide an his-
toric United States commitment to the global eradication 
of TB, including to the successful treatment of 4,500,000 
new TB patients and 90,000 new multi-drug resistant 
(MDR) TB cases by 2013, while providing additional 
treatment through coordinated multilateral efforts; 
Whereas the United States Agency for International Develop-
ment provides financial and technical assistance to nearly 
40 highly-burdened TB countries and supports the devel-
opment of new diagnostic and treatment tools, and is au-
thorized to support research to develop new vaccines to 
combat TB; 
Whereas the Centers for Disease Control and Prevention, 
working in partnership with States and territories of the 
United States, directs the national TB elimination pro-
gram and essential national TB surveillance, technical as-
sistance, prevention activities and supports the develop-
ment of new diagnostic, treatment and prevention tools 
to combat TB; 
Whereas the National Institutes of Health, through its many 
institutes and centers, plays the leading role in basic and 
clinical research into the identification, treatment and 
prevention of TB; 
Whereas the Global Fund to Fight AIDS, Tuberculosis and 
Malaria provides 63 percent of all international financing
•HRES 1155 EH 
for TB programs worldwide and finances proposals worth 
$3,200,000,000 in 112 countries, and TB treatment for 
6,000,000 and HIV/TB services for 1,800,000, and in 
many countries in which the Global Fund supports pro-
grams, TB prevalence is declining, as are TB mortality 
rates; and 
Whereas March 24, 2010, is World Tuberculosis Day, a day 
that commemorates the date in 1882 when Dr. Robert 
Koch announced his discovery of Mycobacterium tuber-
culosis, the bacteria that causes tuberculosis: Now, there-
fore, be it 
Resolved, That the House of Representatives— 
(1) supports the goals of World TB Day to raise 
awareness about tuberculosis; 
(2) commends the progress made by United States- 
led anti-tuberculosis programs; and 
(3) reaffirms its commitment to global tuberculosis 
control made through the Tom Lantos and Henry J. 
Hyde United States Global Leadership Against HIV/ 
AIDS, Tuberculosis, and Malaria Reauthorization Act of 
2008. 
Attest: 
Clerk.